American Regent

American Regent, founded in 1999, is a prominent pharmaceutical company specializing in the development, manufacturing, and supply of high-quality sterile injectables. As a subsidiary of the Daiichi Sankyo Group, the firm provides essential therapeutic solutions for healthcare providers, clinics, and hospitals throughout the United States and Canada. Their diverse product portfolio includes human and veterinary pharmaceuticals, such as Adequan, iron supplements, and various IV medications designed to meet critical clinical needs.

The company maintains a robust operational footprint with 6 locations across New York, Ohio, and Pennsylvania, supported by a workforce of 500-1,000 employees. American Regent leverages advanced manufacturing capabilities to ensure the consistent delivery of generic and specialized injectable products. Their operational strategy focuses on maintaining high standards in sterile production, ensuring that healthcare facilities have reliable access to necessary medical supplies for patient care and therapeutic interventions.

Operating within a competitive landscape, American Regent generates $321.7M in annual revenue and faces industry rivals such as Amphastar Pharmaceuticals, Sagent Pharmaceuticals, and PAI Pharma. The company’s integration within the Daiichi Sankyo Group provides significant market stability and resources. Meet American Regent's team to learn more about the leadership and organizational structure driving their pharmaceutical innovations. By maintaining a strong B2B focus and nationwide sales territories, the company continues to expand its influence in the North American healthcare sector, consistently delivering value through its specialized injectable product lines and commitment to medical excellence.